Othera Pharmaceuticals And The National Eye Institute Collaborate In Dry AMD Study

EXTON, Pa.--(BUSINESS WIRE)--April 5, 2006--Othera Pharmaceuticals, Inc. today announced the initiation of a Phase II clinical trial by the National Eye Institute (NEI) of Othera's topical eye drop OT-551 in patients with Geographic Atrophy (GA), a sign of dry or atrophic Age-Related Macular Degeneration (AMD). The NEI will investigate OT-551's potential to slow enlargement of the atrophic area in the macula and prevent progression to the vision-threatening advanced stages of AMD.

Back to news